Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MADRIGAL PHARMACEUTICALS, INC. Director's Dealing 2012

Jul 27, 2012

30608_dirs_2012-07-27_a73302eb-03ba-4130-a5b2-4c3f0ee03cc7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-07-25

Reporting Person: Kovner Bruce (Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-25 Common Stock A 3081664 $6.49 Acquired 8006852 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 125000 Indirect
Common Stock 125000 Indirect
Common Stock 125000 Indirect
Common Stock 125000 Indirect
Common Stock 475000 Indirect
Common Stock 475000 Indirect
Common Stock 475000 Indirect
Common Stock 475000 Indirect
Common Stock 7761716 Indirect

Footnotes

F1: These shares are owned directly by CxSynta LLC and indirectly by the Reporting Person as sole shareholder of Caxton Corporation, the managing member of CxSynta LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.